EyePoint Pharmaceuticals Inc [EYPT] stock is trading at $9.10, up 2.48%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EYPT shares have gain 14.18% over the last week, with a monthly amount glided 20.05%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] stock has seen the most recent analyst activity on August 28, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $15. Previously, JP Morgan started tracking the stock with Overweight rating on January 22, 2024, and set its price target to $35. On November 02, 2023, Mizuho initiated with a Buy rating and assigned a price target of $20 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $33 on April 21, 2023. Chardan Capital Markets initiated its recommendation with a Buy and recommended $21 as its price target on July 07, 2022. Cowen started tracking with a Outperform rating for this stock on March 01, 2021, and assigned it a price target of $25. In a note dated January 28, 2021, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $22 on this stock.
EyePoint Pharmaceuticals Inc [EYPT] stock has fluctuated between $5.67 and $30.99 over the past year. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] shares were valued at $9.10 at the most recent close of the market. An investor can expect a potential return of 229.67% based on the average EYPT price forecast.
Analyzing the EYPT fundamentals
EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] reported sales of 50.39M for the trailing twelve months, which represents a growth of 4.09%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -1.96%, Pretax Profit Margin comes in at -1.72%, and Net Profit Margin reading is -1.72%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.43 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.82 points at the first support level, and at 8.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.55, and for the 2nd resistance point, it is at 10.00.
Ratios To Look Out For
For context, EyePoint Pharmaceuticals Inc’s Current Ratio is 4.75. Further, the Quick Ratio stands at 4.69, while the Cash Ratio is 1.46. Considering the valuation of this stock, the price to sales ratio is 9.67, the price to book ratio is 2.08.
Transactions by insiders
Recent insider trading involved DICICCO WENDY F, Director, that happened on Aug 20 ’24 when 2567.0 shares were purchased. Director, ANDO GORAN completed a deal on Aug 21 ’24 to buy 5000.0 shares. Meanwhile, Director Zaderej Karen L. bought 12500.0 shares on Aug 19 ’24.
